Drug Resistance & Access: A Nordic initiative is pushing a new way to fight antimicrobial resistance by coordinating cross-border antibiotic purchasing and guaranteeing supplier remuneration, with a pilot expected soon—an approach that could matter for Liechtenstein’s access to essential medicines. Rare Disease Treatment Update: Neuren Pharmaceuticals’ DAYBUE (trofinetide) got a positive European Medicines Agency CHMP opinion for marketing authorization for neurobehavioral symptoms of Rett syndrome, moving to a final European Commission decision; if approved, it would be the first EU-authorized option for this indication. Osteoporosis Medicine Expansion: The European Commission authorized CinnaGen’s Zandoriah® (teriparatide) for adult osteoporosis across EU27 plus Iceland, Liechtenstein and Norway, setting up broader availability subject to local rules. Transplant Medicine Rights: SERB Pharmaceuticals completed acquisition of EU/UK/Swiss/Liechtenstein rights to Idefirix® (imlifidase), aiming to expand access for patients needing time-critical transplant options. Cross-Border Care Basics: A new explainer breaks down how cross-border healthcare works in Europe—who can use it, what costs are covered, and when prior authorization applies. Local Mobility for Health Needs: Guidance notes that people with a UK Blue Badge may use it in Liechtenstein and other countries with reciprocal parking arrangements, helping disabled travellers park closer. Trade & Health System Context: Vietnam and EFTA (including Liechtenstein) concluded free trade agreement talks, covering areas like sanitary measures and cooperation—potentially shaping future health-related trade and collaboration.